ADA

ADA 2024: Screening for hypercortisolism may be key to managing difficult-to-treat T2DM

June 26, 2024

Hypercortisolism may be the culprit behind difficult-to-control T2DM for many patients, according to findings from the CATALYST study. These findings were presented at the recent American Diabetes Association’s 84th Scientific Sessions …

• Investigators screened over 1,000 individuals with HbA1c levels between 7.5-11.5% despite multiple diabetes therapies. An overnight 1 mg dexamethasone suppression test (DST) was used to detect hypercortisolism.
• Hypercortisolism was detected in 24% of patients. Among those taking ≥3 hypertension therapies, the prevalence of hypercortisolism was approximately 33%.
• CT scans revealed adrenal abnormalities in about one-third of these patients, and one-quarter had an adrenal tumor.

Source:

(2024, June 24). American Diabetes Association. One in four patients with difficult-to-control type 2 diabetes experience high levels of cortisol. https://diabetes.org/newsroom/press-releases/one-four-patients-difficult-control-type-2-diabetes-experience-high-levels